Optimizing HCV Screening to Maximize Health Benefit Among Men Who Have Sex with Men in the United States: A Cost-Effectiveness Analysis

Clicks: 27
ID: 321229
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #196 of 552 articles by views in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 552 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND: Current US guidelines recommend annual HCV screening among men who have sex with men (MSM) with HIV and MSM on pre-exposure prophylaxis against HIV (PrEP), but these recommendations were based largely on expert opinion using interferon-era assumptions. METHODS: We calibrated a dynamic economic model of HCV transmission among MSM to US data to determine the cost-effectiveness of HCV testing among MSM with HIV and/or using PrEP; and among MSM not using PrEP, compared to status quo HCV testing. Program costs and quality-adjusted life years (QALYs) were calculated to determine the mean incremental cost-effectiveness ratio (ICER) of each testing combination compared to its next least costly permutation. We defined the optimal strategy as that having the highest health benefits but with an ICER below a willingness-to-pay threshold of $100,000/QALY gained. RESULTS: Six testing strategies dominated the other combinations. Implementing recommended annual screening among MSM with HIV was cost-saving compared to current testing rates. However, the optimal strategy was testing MSM with HIV every 6 months, MSM using PrEP every 12 months, and MSM not using PrEP when tested for HIV (ICER $67,092/QALY gained). The optimal strategy did not change under sensitivity analyses. CONCLUSIONS: The optimal frequency of HCV testing to achieve maximum health benefit in a cost-effective manner for MSM in the US is higher in two subgroups, MSM with HIV, and MSM not using PrEP, than current US guidelines recommend. HCV testing is currently performed less frequently than optimal. Expanding testing is needed to improve HCV outcomes among MSM in the US.
Reference Key
openalex_W7168360615 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Natasha K Martin, Antoine Chaillon, Peter Vickerman, Louis MacGregor, Chidozie Williams Chukwu, Adriane Wynn, Daniel S Fierer
Journal Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Year 2026
DOI
10.1093/cid/ciag416
URL
https://doi.org/10.1093/cid/ciag416
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.